Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

This study has been terminated.
(Poor recruitment)
Information provided by (Responsible Party):
AEterna Zentaris Identifier:
First received: September 21, 2012
Last updated: January 14, 2014
Last verified: May 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: October 2014
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)